In addition to strong sales figures, Theravance announced an organizational restructuring aimed at reducing operating expenses by approximately 60%. This restructuring is expected to generate annualized cash flow of $60 to $70 million starting in Q3 2026. The company also reported a net income of $61 million for Q4 2025, a significant turnaround from a net loss of $15.5 million in the same period last year. This improvement was driven by milestone payments and increased sales from both YUPELRI and TRELEGY, which also triggered a $50 million milestone payment due to its strong performance.
The company’s strategic review committee is actively evaluating opportunities to maximize shareholder value, including potential strategic alternatives following the results of the Phase 3 CYPRESS study of ampreloxetine, which did not meet its primary endpoint. The committee is working with Lazard, its independent financial advisor, to explore various options, including a potential sale of the company. Theravance Biopharma remains committed to delivering value to its shareholders and is focused on its core commercial asset, YUPELRI, as it navigates these changes.
